Biogen. has been granted a patent for anti-VLA-4 antibodies and their binding fragments, including methods for treating multiple sclerosis and epilepsy. The patent also covers polynucleotides encoding these antibodies and specific sequences for their variable and constant regions. GlobalData’s report on Biogen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Biogen, Personalized cancer vaccines was a key innovation area identified from patents. Biogen's grant share as of June 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-vla-4 antibodies for treating multiple sclerosis and epilepsy
The patent US12037398B2 describes a series of claims related to recombinant anti-alpha 4 antibodies and their fragments, which are engineered for therapeutic applications, particularly in treating conditions like multiple sclerosis. The antibodies are characterized by specific variable light and heavy chain sequences, as well as human kappa light chain constant regions. Notably, the heavy chain constant regions are derived from human IgG1 or IgG4 isotypes and include various mutations aimed at enhancing stability and reducing susceptibility to scrambling, a phenomenon that can affect antibody efficacy. The claims detail the specific sequences and mutations, providing a comprehensive framework for the design of these antibodies.
Additionally, the patent outlines methods for producing these recombinant antibodies using host cells, specifically Chinese hamster ovary (CHO) cells, which are commonly used in biopharmaceutical production. The methods involve transfecting the host cells with polynucleotides encoding the desired heavy and light chains, followed by culturing the cells to produce the antibodies. The claims also emphasize the potential therapeutic applications of these antibodies, particularly in alleviating symptoms associated with multiple sclerosis, highlighting their significance in the field of immunotherapy. Overall, the patent presents a detailed approach to developing engineered antibodies with improved properties for clinical use.
To know more about GlobalData’s detailed insights on Biogen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
